• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种无辅料、无副产物的水溶性紫杉醇前药新方法:异紫杉醇的设计与合成

A novel approach of water-soluble paclitaxel prodrug with no auxiliary and no byproduct: design and synthesis of isotaxel.

作者信息

Hayashi Yoshio, Skwarczynski Mariusz, Hamada Yoshio, Sohma Youhei, Kimura Tooru, Kiso Yoshiaki

机构信息

Department of Medicinal Chemistry, Center for Frontier Research in Medicinal Science, Kyoto Pharmaceutical University, Yamashina-Ku, Kyoto 607-8412 Japan.

出版信息

J Med Chem. 2003 Aug 28;46(18):3782-4. doi: 10.1021/jm034112n.

DOI:10.1021/jm034112n
PMID:12930140
Abstract

A novel water-soluble paclitaxel prodrug, isotaxel 2, that realizes a higher water-solubility and the formation of paclitaxel through a simple pH-dependent chemical mechanism via the O-N acyl migration was synthesized and showed promising results in water-solubility and kinetics. This prodrug, a 2'-O-benzoyl isoform of paclitaxel, has no additional functional auxiliaries released during conversion to paclitaxel, which would be a great advantage in toxicology and medical economics.

摘要

一种新型水溶性紫杉醇前药异紫杉醇2被合成出来,它通过O-N酰基迁移这种简单的pH依赖化学机制实现了更高的水溶性并生成紫杉醇,在水溶性和动力学方面显示出有前景的结果。这种前药是紫杉醇的2'-O-苯甲酰异构体,在转化为紫杉醇的过程中没有额外的功能性助剂释放出来,这在毒理学和医学经济学方面将是一个很大的优势。

相似文献

1
A novel approach of water-soluble paclitaxel prodrug with no auxiliary and no byproduct: design and synthesis of isotaxel.一种无辅料、无副产物的水溶性紫杉醇前药新方法:异紫杉醇的设计与合成
J Med Chem. 2003 Aug 28;46(18):3782-4. doi: 10.1021/jm034112n.
2
No auxiliary, no byproduct strategy for water-soluble prodrugs of taxoids: scope and limitation of O-N intramolecular acyl and acyloxy migration reactions.紫杉烷类水溶性前药的无辅助、无副产物策略:O-N分子内酰基和酰氧基迁移反应的范围和局限性
J Med Chem. 2005 Apr 7;48(7):2655-66. doi: 10.1021/jm049344g.
3
O-N intramolecular acyl migration reaction in the development of prodrugs and the synthesis of difficult sequence-containing bioactive peptides.前药开发及含难合成序列生物活性肽合成中的O-N分子内酰基迁移反应
Biopolymers. 2004;76(4):344-56. doi: 10.1002/bip.20136.
4
Development of first photoresponsive prodrug of paclitaxel.紫杉醇首个光响应前药的研发。
Bioorg Med Chem Lett. 2006 Sep 1;16(17):4492-6. doi: 10.1016/j.bmcl.2006.06.030. Epub 2006 Jun 27.
5
Development of novel water-soluble photocleavable protective group and its application for design of photoresponsive paclitaxel prodrugs.新型水溶性光可裂解保护基的开发及其在光响应性紫杉醇前药设计中的应用。
Bioorg Med Chem. 2008 May 15;16(10):5389-97. doi: 10.1016/j.bmc.2008.04.022. Epub 2008 Apr 15.
6
New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy.为癌症化疗中的抗体导向酶解前药疗法(ADEPT)和前体药物疗法(PMT)设计的新型紫杉醇前药。
Bioorg Med Chem. 2006 Jul 15;14(14):5012-9. doi: 10.1016/j.bmc.2006.03.002. Epub 2006 Mar 22.
7
Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.HIV-1蛋白酶抑制剂KNI-727的水溶性前药的开发:基于自发化学裂解的前药更高胃肠道吸收的转化时间的重要性。
J Med Chem. 2003 Sep 11;46(19):4124-35. doi: 10.1021/jm030009m.
8
O-N intramolecular acyl migration strategy in water-soluble prodrugs of taxoids.紫杉烷类水溶性前药中的O-N分子内酰基迁移策略
Bioorg Med Chem Lett. 2003 Dec 15;13(24):4441-4. doi: 10.1016/j.bmcl.2003.09.020.
9
Drug delivery systems: water soluble taxol 2'-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness.药物递送系统:水溶性紫杉醇2'-聚乙二醇酯前药——设计与体内有效性
J Med Chem. 1996 Jan 19;39(2):424-31. doi: 10.1021/jm950475e.
10
Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT).喜树碱水溶性葡糖醛酸衍生物的设计与合成,用于癌症前药单一疗法和抗体导向酶前药疗法(ADEPT)。
J Med Chem. 1999 Sep 9;42(18):3623-8. doi: 10.1021/jm990124q.

引用本文的文献

1
Conjugation of Paclitaxel to Hybrid Peptide Carrier and Biological Evaluation in Jurkat and A549 Cancer Cell Lines.紫杉醇与杂合肽载体的偶联及其在Jurkat和A549癌细胞系中的生物学评价。
ACS Med Chem Lett. 2017 Jul 27;8(8):814-819. doi: 10.1021/acsmedchemlett.7b00117. eCollection 2017 Aug 10.
2
Prodrug Strategies for Paclitaxel.紫杉醇的前药策略
Int J Mol Sci. 2016 May 23;17(5):796. doi: 10.3390/ijms17050796.
3
Novel Type of Prodrug Activation through a Long-Range O,N-Acyl Transfer: A Case of Water-Soluble CREB Inhibitor.
通过远程O,N-酰基转移实现的新型前药激活:水溶性CREB抑制剂的案例
ACS Med Chem Lett. 2014 Aug 22;5(10):1104-9. doi: 10.1021/ml500330n. eCollection 2014 Oct 9.
4
Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma.载共轭亚油酸-紫杉醇(CLA-PTX)的 iRGD 修饰脂质体对 B16-F10 黑色素瘤的抗肿瘤作用。
Int J Nanomedicine. 2014 Jun 24;9:3091-105. doi: 10.2147/IJN.S65664. eCollection 2014.
5
2'-Behenoyl-paclitaxel conjugate containing lipid nanoparticles for the treatment of metastatic breast cancer.含 2'-二十二酰基紫杉醇的载药脂质纳米粒治疗转移性乳腺癌。
Cancer Lett. 2013 Jul 1;334(2):253-62. doi: 10.1016/j.canlet.2012.08.009. Epub 2012 Aug 16.
6
Improved biochemical strategies for targeted delivery of taxoids.用于靶向递送紫杉烷类化合物的改进生化策略。
Bioorg Med Chem. 2007 Jun 1;15(11):3597-623. doi: 10.1016/j.bmc.2007.03.041. Epub 2007 Mar 18.